1. bookVolume 65 (2019): Edizione 1 (March 2019)
Dettagli della rivista
License
Formato
Rivista
eISSN
2449-8343
Prima pubblicazione
04 Apr 2014
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Accesso libero

Impact of Curcuma longa extract on the expression level of brain transporters in in vivo model

Pubblicato online: 02 May 2019
Volume & Edizione: Volume 65 (2019) - Edizione 1 (March 2019)
Pagine: 32 - 39
Ricevuto: 06 Feb 2019
Accettato: 20 Mar 2019
Dettagli della rivista
License
Formato
Rivista
eISSN
2449-8343
Prima pubblicazione
04 Apr 2014
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese

1. Sarrazin JL, Bonneville F, Martin-Blondel G. Brain infections. Diagn Interv Imaging 2012; 93(6):473-90. doi: http://dx.doi.org/10.1016/j.diii.2012.04.02010.1016/j.diii.2012.04.02022677301Apri DOISearch in Google Scholar

2. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014; 55(4):475-82. doi: http://dx.doi.org/10.1111/epi.1255010.1111/epi.1255024730690Apri DOISearch in Google Scholar

3. Saatman KE, Duhaime AC, Bullock R, Maas AIR, Valadka A, Manley GT, et al. Classification of traumatic brain injury for targeted therapies. J Neurotrauma 2008; 25(7):719-38. doi: http://dx.doi.org/10.1089/neu.2008.058610.1089/neu.2008.0586272177918627252Apri DOISearch in Google Scholar

4. McFaline-Figueroa JR, Lee EQ. Brain Tumors. Am J Med 2018; 131(8):874-882. doi: http://dx.doi.org/10.1016/j.amjmed.2017.12.03910.1016/j.amjmed.2017.12.03929371158Search in Google Scholar

5. Seifert HA, Offner H. The splenic response to stroke: from rodents to stroke subjects. J Neuroinflammation 2018; 5:195. doi: http://dx.doi.org/10.1186/s12974-018-1239-910.1186/s12974-018-1239-9603073629970193Apri DOISearch in Google Scholar

6. Florendo M, Figacz A, Srinageshwar B, Sharma A, Swanson D, Dunbar GL, et al. Use of polyamidoamine dendrimers in brain diseases. Molecules 2018; 23(9):2238. doi: http://dx.doi.org/10.3390/molecules2309223810.3390/23092238Apri DOISearch in Google Scholar

7. Chen M, Du ZY, Zheng X, Li DL, Zhou RP, Zhang K. Use of curcumin in diagnosis, prevention, and treatment of Alzheimer’s disease. Neural Regen Res 2018; 13(4):742-752. doi: http://dx.doi.org/10.4103/1673-5374.23030310.4103/1673-5374.230303595068829722330Apri DOISearch in Google Scholar

8. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer’s disease: An overview. Ann Indian Acad Neurol 2008; 11(1):13–19. doi: http://dx.doi.org/10.4103/0972-2327Search in Google Scholar

9. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37(1):13-25. doi: http://dx.doi.org/10.1016/j.nbd.2009.07.03010.1016/j.nbd.2009.07.03019664713Apri DOISearch in Google Scholar

10. Daneman R, Prat A. The blood–brain barrier. Cold Spring Harb Perspect Biol 2015; 7(1):a020412. doi: http://dx.doi.org/10.1101/cshperspect.a02041210.1101/cshperspect.a020412429216425561720Search in Google Scholar

11. Moretti R, Chhor V, Titomanlio L, Fleiss B, Gressens P. Brain edema in developing brain diseases. In: Brain edema. From molecular mechanisms to clinical practice. London 2017:393-429.10.1016/B978-0-12-803196-4.00021-7Search in Google Scholar

12. Tajes M, Ramos-Fernández E, Weng-Jiang X, Bosch-Morató M, Guivernau B, Eraso-Pichot A, et al. The blood-brain barrier: structure, function and therapeutic approaches to cross it. Mol Membr Biol 2014; 31(5):152-67. doi: http://dx.doi.org/10.3109/09687688.2014.93746810.3109/09687688.2014.93746825046533Apri DOISearch in Google Scholar

13. Schenk GJ, Kooij G, Reijerkerk A, de Vries H. Disease influence on BBB transport in inflammatory disorders. In: Hammarlund-Udenaes M, de Lange E, Thorne R. (eds.). Drug delivery to the brain. AAPS advances in the pharmaceutical sciences. New York 2014, 10:573-589.10.1007/978-1-4614-9105-7_21Search in Google Scholar

14. Bogacz A, Deka-Pawlik D, Bartkowiak-Wieczorek J, Karasiewicz M, Kujawski R, Kowalska A, et al. The effect of herbal materials on the P-glycoprotein activity and function. Herba Pol 2013; 59(4):129-141. doi: http://dx.doi.org/10.2478/hepo-2013-002910.2478/hepo-2013-0029Apri DOISearch in Google Scholar

15. Young AB. Four decades of neurodegenerative disease research: How far we have come! J Neurosci 2009; 29(41):12722-12728. doi: http://dx.doi.org/10.1523/JNEUROSCI.3767-09.200910.1523/JNEUROSCI.3767-09.2009280766819828782Apri DOISearch in Google Scholar

16. Zhang F, Lin Y, Kannan S, Kanan RM. Targeting specific cells in the brain with nanomedicines for CNS therapies. J Control Release 2016; 240:212–226. doi: http://dx.doi.org/10.1016/j.jconrel.2015.12.01310.1016/j.jconrel.2015.12.013490308926686078Apri DOISearch in Google Scholar

17. Mrozikiewicz PM, Bogacz A, Bartkowiak-Wieczorek J, Kujawski R, Mikołajczak PL, et al. Screening for impact of popular herbs improving mental abilities on the transcriptional level of brain transporters. Acta Pharm 2014; 64(2):223-32. doi: http://dx.doi.org/10.2478/acph-2014-002010.2478/acph-2014-002024914722Apri DOISearch in Google Scholar

18. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 2009; 65(11):1063-70. doi: http://dx.doi.org/10.1007/s00228-009-0714-810.1007/s00228-009-0714-819727692Apri DOISearch in Google Scholar

19. Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv 2013; 10(7):889-905. doi: http://dx.doi.org/10.1517/17425247.2013.78474210.1517/17425247.2013.78474223550609Apri DOISearch in Google Scholar

20. Zhang R, Jie J, Zhou Y, Cao Z, Li W. Longterm effects of Panax ginseng on disposition of fexofenadine in rats in vivo. Am J Chin Med 2009; 37:657-667. doi: http://dx.doi.org/10.1142/S0192415X0900714410.1142/S0192415X0900714419655405Apri DOISearch in Google Scholar

21. Zhang J, Zhou F, Wu X, Gu Y, Ai H, Zheng Y, et al. 20(S)-ginsenoside Rh2 noncompetitively inhibits P-glycoprotein in vitro and in vivo: a case for herb–drug interactions. Drug Metab Dispos 2010; 38:2179–2187. doi: http://dx.doi.org/10.1124/dmd.110.03479310.1124/dmd.110.03479320837659Apri DOISearch in Google Scholar

22. Garrovo Ch, Rosati A, Bartoli F, Decorti G. St John’s wort modulation and developmental expression of multidrug transporters in the rat. Phytother Res 2006; 20:468-473. doi: http://dx.doi.org/10.1016/j.taap.2004.04.02010.1016/j.taap.2004.04.02015504456Apri DOISearch in Google Scholar

23. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemoth Pharm 1994; 34:459-464. doi: http://dx.doi.org/10.1371/journal.pone.005176410.1371/journal.pone.0051764351988623240061Apri DOISearch in Google Scholar

24. Yuan J, Liu W, Zhu H, Zhang X, Feng Y, Chen Y, et al. Curcumin attenuates blood-brain barrier dis ruption after subarachnoid hemorrhage in mice. J Surg Res 2017; 207:85-91. doi: http://dx.doi.org/10.1016/j.jss.2016.08.09010.1016/j.jss.2016.08.09027979493Apri DOISearch in Google Scholar

25. Wang YF, Gu YT, Qin GH, Zhong L, Meng YN. Curcumin ameliorates the permeability of the blood-brain barrier during hypoxia by upregulating heme oxygenase-1 expression in brain microvascular endothelial cells. J Mol Neurosci 2013; 51(2):344-351. doi: http://dx.doi.org/10.1007/s12031-013-9989-410.1007/s12031-013-9989-423494637Apri DOISearch in Google Scholar

26. Klinger NV, Mittal S. Therapeutic potential of curcumin for the treatment of brain tumors. Oxid Med Cell Longev 2016; 2016:9324085. doi: http://dx.doi.org/10.1155/2016/932408510.1155/2016/9324085507865727807473Apri DOISearch in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo